Tirasemtiv – detailed trial results to be announced next week

Reading Time: < 1 minute

Cytokinetics have published a press release of their ‘top line’ results for their drug Tirasemtiv. Unfortunately, the results are disappointing.

The main aim of their most recent clinical trials was to see if there was a slower rate of progression (measured by a widely used MND clinical scale called the ALSFRS) in people with MND taking tirasemtiv compared to those taking the dummy drug. The researchers didn’t find any difference in ALSFRS scores. They’re currently analysing the results for beneficial effects on other symptoms of MND.

The full results will be presented at the American Academy of Neurology conference next week. Sam is working on a more detailed article after these have been presented.   More information about tirasemtiv can be found on our website. The press release announcing these ‘top line’ results can be found here.

Dr Belinda Cupid, Head of Research at the MND Association said: “MND clinical trials give us all new hope that something can be done to slow the progression of the disease, and it’s devastating when those trials don’t show any benefit. It emphasizes why we have to continue to fund research – finding the cause and source of the disease and then working out how to stop it.”

3 thoughts on “Tirasemtiv – detailed trial results to be announced next week

  1. Hi Belinda, thanks for the update. It’s disappointing that Tirasemtiv is showing only marginal benefits at best. My belief is that truly effective treatments will only come once we’ve developed a better understanding of the reasons behind the onset and development of MND and I applaud the MNDA’s continued support of vital basic research. The approach of using likely looking compounds on the off chance that something might work has been the mainstay of the pharmaceutical industry for many years now but its success rate has been poor. Whilst I’m not knocking the chance of finding another Riluzole (or preferably something better) what the community needs is something that can improve a patient’s condition rather than just slow progression. From what I’ve seen none of the compounds currently in clinical trials (other than stem cell therapies) really promise to do that. I’ll certainly look forward to hearing about results from future clinical trials and obviously hope something significant turns up but in the meantime I’ll keep reading your regular research updates to watch the jigsaw puzzle being slowly put together. As a suggestion, would it be possible to include research that wasn’t funded by the MNDA as regular items on this blog?
    Thanks again,
    Colin Fenwick

    1. Hi Colin,

      Thank you for commenting on the blog post and giving us feedback. In response to your question, we do write about various research in the news that is not funded by the Association. However, in response to your feedback, we will aim to increase our blog coverage on these research topics in the future.

      Best wishes,
      Research Information Co-ordinator
      Research Development team, MND Association, UK

  2. Pingback: Tirasemtiv Phase II clinical trial – results | MND Research

Comments are closed.